Russmann Stefan, Lamerato Lois, Motsko Stephen P, Pezzullo John C, Faber Mark D, Jones Judith K
The Degge Group, Arlington, Virginia 22209, USA.
Am J Gastroenterol. 2008 Nov;103(11):2707-16. doi: 10.1111/j.1572-0241.2008.02201.x. Epub 2008 Oct 17.
The aim of this study was to estimate the risk of further creatinine increase in patients with preexisting renal disease after the use of oral sodium phosphate (OSP) versus polyethylene glycol (PEG), and to study usage patterns of OSP in relation to renal function.
A cohort study was done using clinical records and electronic patient information from the Henry Ford Health System (HFHS) in patients who had used either OSP or PEG for colonoscopy between February 1999 and April 2006. Among patients with an estimated GFR < 60 ml/min before colonoscopy, we identified cases with an unexplained creatinine increase of > or = 0.5 mg/dl within 14 days after colonoscopy.
We identified 7,971 OSP and 1,511 PEG users. Relative use of OSP versus PEG decreased from 88.0% before 2004 to 48.4% in 2006. 70.2% of OSP users had no recorded creatinine determination within 60 days before colonoscopy, and this proportion did not decrease over time. The study population included 317 patients with a baseline GFR < 60 ml/min, and we identified one case with an unexplained creatinine increase > or = 0.5 mg/dl among 191 PEG users (0.5%) versus eight cases among 126 OSP users (6.3%). Unadjusted and adjusted relative risk estimates on comparing OSP with PEG were 12.1 (95% CI, 1.5-95.8) and 12.6 (95% CI, 1.5-106.5), respectively.
In patients with preexisting renal disease, OSP use was associated with an increased risk of aggravated renal dysfunction versus PEG. Creatinine measurement with GFR estimation should be done before OSP administration in order to avoid its use in patients with renal disease.
本研究旨在评估已有肾脏疾病的患者在使用口服磷酸钠(OSP)和聚乙二醇(PEG)后肌酐进一步升高的风险,并研究OSP与肾功能相关的使用模式。
采用队列研究,使用亨利福特健康系统(HFHS)1999年2月至2006年4月期间接受结肠镜检查时使用过OSP或PEG的患者的临床记录和电子患者信息。在结肠镜检查前估计肾小球滤过率(GFR)<60 ml/min的患者中,我们确定了结肠镜检查后14天内肌酐不明原因升高≥0.5 mg/dl的病例。
我们确定了7971名OSP使用者和1511名PEG使用者。OSP与PEG的相对使用比例从2004年前的88.0%降至2006年的48.4%。70.2%的OSP使用者在结肠镜检查前60天内未记录肌酐测定值,且这一比例未随时间下降。研究人群包括317名基线GFR<60 ml/min的患者,我们在191名PEG使用者中确定了1例肌酐不明原因升高≥0.5 mg/dl的病例(0.5%),而在126名OSP使用者中有8例(6.3%)。将OSP与PEG进行比较时,未调整和调整后的相对风险估计分别为12.1(95%可信区间,1.5 - 95.8)和12.6(95%可信区间,1.5 - 106.5)。
在已有肾脏疾病的患者中,与PEG相比,使用OSP会增加肾功能恶化的风险。在给予OSP之前应进行肌酐测量并估计GFR,以避免在肾病患者中使用。